Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.
Jenny F SeligmannDavid J FisherLouise C BrownRichard A AdamsJanet GrahamPhilip QuirkeSusan D RichmanRachel ButlerEnric DomingoAndrew BlakeEmma YatesMichael BraunFiona CollinsonRob JonesEwan BrownEmma de WintonTimothy C HumphreyMahesh K B ParmarRichard S KaplanRichard H WilsonMatthew T SeymourTimothy S Maughannull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for RAS/TP53-mutant mCRC. Further testing is required in this sizable population of unmet need.